Know How Tresiba Compares to Other Basal Insulins for Type 2 Diabetes

November 2017

Tresiba (treh-SEE-bah, insulin degludec) is the newest long-acting basal insulin...after Levemir (detemir), Lantus and Basaglar (glargine 100 units/mL), and Toujeo (glargine 300 units/mL).

Tresiba lasts about 42 hours...compared to about 24 hours for Levemir, Lantus, or Basaglar...and over 24 hours for Toujeo.

But this doesn't mean that Tresiba works better than the others.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Cholesterol Improve Patient Adherence to Statins
NSAIDs Continue to Limit Celecoxib and Other NSAIDs in High-CV-Risk Patients
Emergency Preparedness Assist Your Patients During a Disaster
Insulin Know How Tresiba Compares to Other Basal Insulins for Type 2 Diabetes
Kidney Disease Explain How to Reduce Itching From Chronic Kidney Disease
Med Administration Don't Be Surprised to See Inhaled Steroids With Sigs to "Swallow"
Pregnancy Help Pregnant Women With Appropriate Opioid Use
Practice Minimize Exposure to Oral Anticancer Drugs in the Community Pharmacy
Interactions Tell Patients to Separate All Oral Meds From Potassium Binders
Antiplatelets Expect Some Stent Patients to Be Switched to Clopidogrel
Practice Explain When Study Results Are Clinically Meaningful to Patients

Know How Tresiba Compares to Other Basal Insulins for Type 2 Diabetes

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents